Answers are grounded in this paper and cite their sources.
In 1997, the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America formed a Task Force to develop classification and outcome measures for myasthenia gravis (MG). The goal of the Task Force was to achieve uniformity in recording and reporting clinical trials and outcomes research. The Task Force met frequently over a three-year period, obtained input from national and international experts, and produced a consensus document on recommendations for MG clinical research standards. In this article, the essential elements of the Task Force's recommendations will be summarized. In addition, several other MG measurement tools that are in various stages of development are mentioned.
No takes yet. Share an insight, caveat, or question.
Richard J. Barohn (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: